Mephenon (Methadone Hydrochloride)

Methadone hydrochloride acts as a full agonist at the μ‑opioid receptor, providing analgesia and suppressing opioid withdrawal. It also blocks NMDA receptors and inhibits the reuptake of serotonin and norepinephrine, which enhances its effectiveness in both pain control and opioid‑dependence therapy.

The dose of Mephenon is individualized. A qualified prescriber determines the appropriate amount based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosing may be adjusted during treatment to achieve optimal efficacy while minimizing adverse effects.

Methadone can be used during pregnancy when the benefits outweigh potential risks, as untreated opioid dependence poses significant hazards to both mother and fetus. Breastfeeding is generally considered acceptable if the infant is monitored for sedation. Clinical judgment and specialist consultation are essential.

To order Mephenon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative for opioid‑dependence maintenance is buprenorphine, a partial μ‑opioid agonist with a ceiling effect on respiratory depression. Methadone provides full agonism and a longer half‑life, allowing once‑daily dosing, but carries a higher risk of respiratory depression and QT prolongation. Choice depends on patient-specific factors and treatment goals.

Mephenon should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken vigorously. Keep the product in its original container until use, and discard any solution that appears discolored or contains particles.

Mephenon is supplied as an injectable solution and may be administered either intramuscularly or intravenously by a qualified healthcare professional. The route, injection site, and infusion rate are determined by the prescriber based on the therapeutic indication and patient tolerance.

The most critical risks include respiratory depression, which can be fatal if not promptly recognized, and cardiac arrhythmias due to QT interval prolongation. Patients should be monitored for signs of excessive sedation, shallow breathing, and irregular heart rhythms, especially when combined with other CNS depressants.

Mephenon is contraindicated in individuals with severe uncontrolled respiratory depression, acute asthma attacks, or known hypersensitivity to methadone or any formulation components. Caution is also advised for patients with significant cardiac conduction disorders, untreated severe liver disease, or those taking multiple QT‑prolonging medications.